Kane Biotech: Commercialization Pillars

Posted in: News

Kane Biotech is creating smarter ways to fight bacteria and leading the advancement of technologies and products that break up biofilms and destroy bacteria in three commercialization pillars: animal health, wound & surgical care, and dermatology. Kane has been at the forefront for research and development to address the issues of biofilms with 81 patents and patents pending. Why are biofilms so important?

WHAT ARE BIOFILMS?

Biofilms are a glue-like substance excreted by bacteria and/or fungi to attach to surfaces. Biofilms protect and allow bacteria to survive and thrive in hostile environments. Biofilms make bacteria up to 1,000 times more resistant to antibiotics and antimicrobials. Biofilms are one of the main contributors to antibiotic resistance.

To learn more about biofilms, click to view: UNDERSTANDING BIOFILMS VIDEO


WOUND & SURGICAL CARE

Biofilm impaired healing is the largest unresolved problem in Wound Care.
Biofilms are pervasive and represent the most prevalent bacterial mode of growth. The current wound care global market is expected to reach US $22 billion in 2022.

Kane’s DispersinB® Wound Gel:
Kane’s DispersinB® wound gel is set to begin human clinical studies in 2022. Previously, the wound gel had undergone extensive pre-clinical testing regimen showing it to be safe, non-toxic and non-irritating, as well as passing all biocompatibility testing. In addition, DispersinB® wound gel significantly accelerated the healing of both infected and non-infected dermal wounds compared to controls. Developed by Kane Biotech, DispersinB® wound gel is designed to accelerate healing of Stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second-degree burns, and grafted and donor sites.

Studies have reported a prevalence of biofilms in over 78% of chronic wounds. The Centers for Disease Control and Prevention (CDC) has identified resistant bacteria, which biofilms are a major contributor, as being a serious and urgent clinical and financial burden to health care systems and patients. Antibiotic resistance (AR) is predicted to be the next global pandemic.

Kane’s coactiv+™ technology:
In 2021, Kane Biotech announced it was developing a wound gel based on their coactiv+™ technology. The coactiv+™ gel firms up a higher temperature which is contrary to most gelling systems. Below 20 degrees Celsius (68 Fahrenheit), it will liquify because it is thermo-reversible. When cold, the gel is very easy to apply and soothing for sensitive wounds such as burns. It can also be rinsed away with cold water which is also soothing to the skin. Once applied to the body, it will stay in place as our body temperature is well above 20 degrees.

To learn more about Kane’s coactiv+™ gel, click to view: COACTIV+™ GEL VIDEO


ANIMAL HEALTH

Biofilms can lead to serious complications in Animal Health.

Kane’s coactiv+™ technology has been used in bluestem™ pet products, including oral care water additive. Bluestem’s coactiv+™ technology is a safe and effective way to soften and break down the biofilm without any harsh chemicals or antimicrobials. Learn more: https://bluestempets.com/

Exclusively available from veterinarians, PLAQTIV+ is a new oral care range of products by Animalcare Ltd that also uses Kane’s coactiv+™ technology for preventative dental care in cats and dogs.
Learn more: https://dental.pet/for-veterinary/plaqtiv

Plaque and tartar are biofilms that cause inflammation, irritation, tooth decay, and loss of teeth for pets.80% of dogs and 70% of cats develop some stage of gum disease by the time they are 3 years old according to the American Veterinary Medical Association (AVMA), and they can lead to serious complications in a pet’s kidneys, heart, and brain.


DERMATOLOGY

Kane Dermatology launched a shampoo, shampoo bar and scalp detoxifier under the DermaKB™ brand in 2020. The retail site offers shampoo products that contain Kane Biotech’s proprietary patented coactiv+™ technology formulated to provide an effective cleansing of the scalp, helping support the reduction of skin irritation and other symptoms associated with common skin disorders. Learn more: www.dermakb.com

Did you know men with facial hair are prone to a fungus called Malassezia? More commonly found in scalp conditions, Malassezia appears to also play a central role in the progression of beard dandruff and seborrheic dermatitis. A beard provides the fungus with protection from the sun and traditional cleansers, causing the fungus to securely attach to the skin and to produce a protective barrier called a biofilm. Recent research from the National Institute of Health has indicated that the persistence of biofilms may be linked with aggravating the symptoms associated with common scalp and skin conditions, such as dandruff and seborrheic dermatitis.

DermaKB™ products weaken and break down the biofilm structure and eliminate product buildup. They leave scalp and hair, including beards, clean – without any harsh chemicals or excessive foam and bubbles. DermaKB™ products are pH balanced, fragrance-free, sulfate-free, and paraben-free.

KANE CONNECTS

6TH ANNUAL CELIA AND SAMUEL RESNIK RESEARCH MEETING
Kane donated $1,500 in support of 6th Annual Celia and Samuel Resnik Research meeting presented by the University of Miami Dr. Phillip Frost Department of Dermatology. This event provides the University of Miami the opportunity to showcase their talented professionals and their outstanding work done in the research field.
INNOVATION HUB @ UNIVERSITY OF MANITOBA
Did you know? Kane Biotech’s offices and laboratories are located in the University of Manitoba Smartpark Innovation Hub. It includes 2 independent analytical laboratories and 3 independent and fully-equipped microbiology suites.
KANE BIOTECH FEATURED ON OTCQB PODCAST
In May, the #OTCQB Podcast featured Kane Biotech (OTCQB: KNBIF) CEO Marc Edwards provided an update on the company’s patents, clinical trials, and biofilm technology.
MEET OUR KANE BIOTECH TEAM: Dr. Nanda Yakandawala
Dr. Yakandawala (known as “Nanda”) joined Kane Biotech in 2003 and is VP of Research & Development. Nanda leads Kane’s research efforts and is passionate about innovation and new product development. Under Nanda’s leadership, Kane’s research team developed the water additive, shampoo, and DispersinB® wound gel. He is a leading expert in biofilms and widely published in this field.

TESTIMONIAL: Personal DermaKB™ Story by David E.

Here is a recent testimonial from David E, who searched everywhere for a solution to his folliculitis condition. Folliculitis is a common skin condition that occurs when a hair follicle becomes infected or inflamed. Most often caused by Staphylococcus aureus (staph) bacteria, it can also be caused by viruses and fungi. Generally uncomfortable and itchy, folliculitis can also have a psychosocial impact due to its appearance, which is similar to acne.

David’s research and perseverance on finding a treatment for his folliculitis condition finally paid off when he found DermaKB™.

“I’ve had folliculitis for 15-20 years. The product is easy to use, it doesn’t look medicinal at all, and there’s no smell,” said David. “I just gave it clean, dry skin to work on, and left it on for that little extra time. Maybe the biofilms had just built up to the point where they were impenetrable. All I know is that since I’ve been using it, everything has improved tremendously. I’m just tickled with the results.”

Kane Dermatology launched a shampoo, shampoo bar and scalp detoxifier under the DermaKB™ brand in 2020, as the first products in their new skin care line. The products are sold direct-to-consumer through Amazon and Kane’s online commerce site: www.dermakb.com.

READ FULL STORY

Share